Figure 2
Pharmacokinetics of Erwinia Asparaginase. (A) Correlation between the observed and model-predicted asparaginase activity in 510 serum samples obtained from 54 patients during the initial course of therapy. The overall goodness of fit of the one-compartment open model with first-order absorption to the experimental data for individual patients is indicated by the closeness of the correlation coefficient (0.94) and slope of the best-fit line (0.86) to unity. (B) Mean serum asparaginase activity-time profile for the six 25 000 IU/m2 intramuscular doses of Erwinia asparaginase given during the first course of therapy for 24 patients receiving the initial dose on a Wednesday. Data points are the geometric mean values of the observed asparaginase activity at each sample time shown together with 1-standard deviation unit error bars. The continuous line is the best-fit curve determined by nonlinear regression analysis of the mean profile.

Pharmacokinetics of Erwinia Asparaginase. (A) Correlation between the observed and model-predicted asparaginase activity in 510 serum samples obtained from 54 patients during the initial course of therapy. The overall goodness of fit of the one-compartment open model with first-order absorption to the experimental data for individual patients is indicated by the closeness of the correlation coefficient (0.94) and slope of the best-fit line (0.86) to unity. (B) Mean serum asparaginase activity-time profile for the six 25 000 IU/m2 intramuscular doses of Erwinia asparaginase given during the first course of therapy for 24 patients receiving the initial dose on a Wednesday. Data points are the geometric mean values of the observed asparaginase activity at each sample time shown together with 1-standard deviation unit error bars. The continuous line is the best-fit curve determined by nonlinear regression analysis of the mean profile.

Close Modal

or Create an Account

Close Modal
Close Modal